Polyclonal IgG biologic immunosuppressant targeting T lymphocytes, administered pre-transplant to prevent GVHD. Depletes and modulates T cells via complement-dependent cytotoxicity, ADCC, and apoptosis; inhibits T-cell activation/proliferation and trafficking; may reduce antigen-presenting cell activity and inflammatory cytokine signaling.
Polyclonal anti–T-lymphocyte IgG that binds multiple T-cell surface antigens and depletes T cells via complement-dependent cytotoxicity, ADCC, and apoptosis; also suppresses T-cell activation/proliferation and trafficking and dampens APC activity and inflammatory cytokine signaling to prevent GVHD.
Polyclonal IgG binds CD7 on T cells, triggering complement-dependent lysis and Fc-mediated ADCC (and apoptosis), leading to depletion of CD7+ cells.
Polyclonal IgG biologic immunosuppressant targeting T lymphocytes, administered pre-transplant to prevent GVHD. Depletes and modulates T cells via complement-dependent cytotoxicity, ADCC, and apoptosis; inhibits T-cell activation/proliferation and trafficking; may reduce antigen-presenting cell activity and inflammatory cytokine signaling.
Polyclonal anti–T-lymphocyte IgG that binds multiple T-cell surface antigens and depletes T cells via complement-dependent cytotoxicity, ADCC, and apoptosis; also suppresses T-cell activation/proliferation and trafficking and dampens APC activity and inflammatory cytokine signaling to prevent GVHD.
ATLG antibodies bind CD25 on T cells and trigger complement-dependent cytotoxicity and Fc-mediated ADCC, causing lysis/apoptosis of CD25+ cells.
Polyclonal IgG biologic immunosuppressant targeting T lymphocytes, administered pre-transplant to prevent GVHD. Depletes and modulates T cells via complement-dependent cytotoxicity, ADCC, and apoptosis; inhibits T-cell activation/proliferation and trafficking; may reduce antigen-presenting cell activity and inflammatory cytokine signaling.
Polyclonal anti–T-lymphocyte IgG that binds multiple T-cell surface antigens and depletes T cells via complement-dependent cytotoxicity, ADCC, and apoptosis; also suppresses T-cell activation/proliferation and trafficking and dampens APC activity and inflammatory cytokine signaling to prevent GVHD.
Polyclonal IgG binds CD28 on T cells; Fc triggers complement-dependent cytotoxicity and ADCC, and cross-linking can induce apoptosis, depleting CD28+ cells.
Polyclonal IgG biologic immunosuppressant targeting T lymphocytes, administered pre-transplant to prevent GVHD. Depletes and modulates T cells via complement-dependent cytotoxicity, ADCC, and apoptosis; inhibits T-cell activation/proliferation and trafficking; may reduce antigen-presenting cell activity and inflammatory cytokine signaling.
Polyclonal anti–T-lymphocyte IgG that binds multiple T-cell surface antigens and depletes T cells via complement-dependent cytotoxicity, ADCC, and apoptosis; also suppresses T-cell activation/proliferation and trafficking and dampens APC activity and inflammatory cytokine signaling to prevent GVHD.
Polyclonal IgG in ATLG binds CD11a on T cells and triggers complement-dependent cytotoxicity and Fc-mediated ADCC, also inducing apoptosis of the bound cells.
Polyclonal IgG biologic immunosuppressant targeting T lymphocytes, administered pre-transplant to prevent GVHD. Depletes and modulates T cells via complement-dependent cytotoxicity, ADCC, and apoptosis; inhibits T-cell activation/proliferation and trafficking; may reduce antigen-presenting cell activity and inflammatory cytokine signaling.
Polyclonal anti–T-lymphocyte IgG that binds multiple T-cell surface antigens and depletes T cells via complement-dependent cytotoxicity, ADCC, and apoptosis; also suppresses T-cell activation/proliferation and trafficking and dampens APC activity and inflammatory cytokine signaling to prevent GVHD.
Polyclonal anti–T-cell IgG binds CD18 (LFA-1 beta) on T cells and induces complement-dependent cytotoxicity and Fc-mediated ADCC, leading to apoptotic/lytic depletion of the bound cells.